450 related articles for article (PubMed ID: 10931408)
1. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
2. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
3. [Early diagnosis of Kawasaki disease complicated by coronary artery lesions].
Hu XH; Xu SX; Luan Z
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):853-5. PubMed ID: 12919919
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of vascular leakage in acute Kawasaki disease.
Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
[TBL] [Abstract][Full Text] [Related]
5. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[TBL] [Abstract][Full Text] [Related]
6. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
Muta H; Ishii M; Egami K; Furui J; Sugahara Y; Akagi T; Nakamura Y; Yanagawa H; Matsuishi T
J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
[TBL] [Abstract][Full Text] [Related]
7. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
8. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
Wilson N; Heaton P; Calder L; Nicholson R; Stables S; Gavin R
J Paediatr Child Health; 2004; 40(9-10):524-9. PubMed ID: 15367145
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.
Mori M; Imagawa T; Katakura S; Miyamae T; Okuyama K; Ito S; Nakamura T; Kimura H; Yokota S
Mod Rheumatol; 2004; 14(1):43-7. PubMed ID: 17028804
[TBL] [Abstract][Full Text] [Related]
10. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease.
Mitani Y; Sawada H; Hayakawa H; Aoki K; Ohashi H; Matsumura M; Kuroe K; Shimpo H; Nakano M; Komada Y
Circulation; 2005 Jan; 111(1):38-43. PubMed ID: 15611368
[TBL] [Abstract][Full Text] [Related]
12. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
[TBL] [Abstract][Full Text] [Related]
13. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
Senzaki H; Kobayashi T; Nagasaka H; Nakano H; Kyo S; Yokote Y; Sasakid N
Pediatr Res; 2003 Jun; 53(6):983-8. PubMed ID: 12621103
[TBL] [Abstract][Full Text] [Related]
15. Intravenous gamma-globulin for Kawasaki disease.
Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
Acta Paediatr Jpn; 1991 Dec; 33(6):799-804. PubMed ID: 1801560
[TBL] [Abstract][Full Text] [Related]
16. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[TBL] [Abstract][Full Text] [Related]
17. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S; Safari M; Amin R
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[TBL] [Abstract][Full Text] [Related]
18. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
20. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
